Literature DB >> 17901820

Hereditary breast-ovarian cancer: clinical findings and medical management.

Megan Marshall1, Sheila Solomon.   

Abstract

Approximately 5% to 10% of breast and ovarian cancers are related to an inherited gene mutation. Of these cases, 84% of hereditary breast cancer and more than 90% of hereditary ovarian cancer are caused by mutations in the BRCA1 or BRCA2 genes. Family histories of cancer are an essential tool in identifying features of and individuals at risk for hereditary breast-ovarian cancer syndrome. The risk to carry an identifiable BRCA gene mutation can be assessed by trained healthcare providers using various pre-test risk models. Individuals who carry a BRCA gene mutation have increased lifetime risks of developing hereditary breast and ovarian cancer syndrome-related cancers. Genetic testing for the BRCA gene mutations is offered in accordance with American Society of Clinical Oncology guidelines. In accordance with guidelines, patients are informed of the risks, benefits, and limitations of testing prior to electing to undergo the testing process. Upon receipt of results, healthcare providers offer the patient with appropriate medical management recommendations.

Entities:  

Mesh:

Year:  2007        PMID: 17901820     DOI: 10.1097/01.PSN.0000290280.48197.e7

Source DB:  PubMed          Journal:  Plast Surg Nurs        ISSN: 0741-5206


  7 in total

1.  Pelvic inflammatory disease and the risk of ovarian cancer: a meta-analysis.

Authors:  Zhiyi Zhou; Fangfang Zeng; Jianhui Yuan; Jinling Tang; Graham A Colditz; Shelley S Tworoger; Britton Trabert; Xuefen Su
Journal:  Cancer Causes Control       Date:  2017-03-24       Impact factor: 2.506

2.  Targeting abnormal DNA repair in therapy-resistant breast cancers.

Authors:  Lisa A Tobin; Carine Robert; Pratik Nagaria; Saranya Chumsri; William Twaddell; Olga B Ioffe; George E Greco; Angela H Brodie; Alan E Tomkinson; Feyruz V Rassool
Journal:  Mol Cancer Res       Date:  2011-11-23       Impact factor: 5.852

3.  Quality in genetic counselling for presymptomatic testing--clinical guidelines for practice across the range of genetic conditions.

Authors:  Heather Skirton; Lesley Goldsmith; Leigh Jackson; Aad Tibben
Journal:  Eur J Hum Genet       Date:  2012-08-15       Impact factor: 4.246

4.  Limited impact on self-concept in individuals with Lynch syndrome; results from a national cohort study.

Authors:  Helle Vendel Petersen; Mary Jane Esplen; Steen Ladelund; Inge Bernstein; Lone Sunde; Christina Carlsson; Mef Nilbert
Journal:  Fam Cancer       Date:  2011-12       Impact factor: 2.375

Review 5.  Targeting abnormal DNA double strand break repair in cancer.

Authors:  Feyruz V Rassool; Alan E Tomkinson
Journal:  Cell Mol Life Sci       Date:  2010-08-10       Impact factor: 9.261

6.  MTHFR C677T polymorphism and breast, ovarian cancer risk: a meta-analysis of 19,260 patients and 26,364 controls.

Authors:  Lilin He; Yongxiang Shen
Journal:  Onco Targets Ther       Date:  2017-01-06       Impact factor: 4.147

7.  Case report: Analysis of BRCA1 and BRCA2 gene mutations in a hereditary ovarian cancer family.

Authors:  Ying Liao; Chunhua Tu; Xiaoxia Song; Liping Cai
Journal:  J Assist Reprod Genet       Date:  2020-04-30       Impact factor: 3.412

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.